Special Issue

Personalized Care for HIV Prevention, Treatment and Cure

Message from the Guest Editor

Great strides have been made in HIV testing and treatment over the last 30 years, the management of HIV can benefit from more individualized care. Personalized medicine (PM) has the potential to tailor prevention and care interventions to optimize safety, effectiveness and patient satisfaction. This Special Issue is focused on describing current personalized medicine approaches to HIV care. This encompasses efforts to deliver individualized care using modern technologies and innovative care models for HIV prevention, comorbidities (hepatitis C, cardiovascular, neurocognitive decline, etc.) and treatment so as to improve the length and quality of life of HIV/AIDS patients. This Special Issue will bring together cuttingedge research across disciplines, including the basic sciences, clinical care and the behavioral and social sciences, in order to better understand and intervene to the benefit of people living with HIV. The aim of this Special Issue is to collate evidence-based manuscripts on relevant topics in the field. Research articles, clinical studies, quantitative and qualitative analyses of pilot studies, meta-analyses, and reviews are all welcome.

Guest Editor

Dr. Bertrand Lebouche

Centre for Outcomes Research & Evaluation, Research Institute of the McGill University Health Centre, 5252 boul de maisonneuve-Office 3C.25, Montreal, QC H4A 3S5, Canada

Deadline for manuscript submissions

closed (5 July 2022)

Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



mdpi.com/si/85769

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm



Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA 2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).